BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

734 related articles for article (PubMed ID: 9209363)

  • 21. DNA-binding domain of AML1, expressed in t(8;21) and t(3;21) myeloid leukemias, inhibits PEBP2/CBF DNA-binding but is not sufficient to transform 32D cl3 myeloid cells.
    Britos-Bray M; Sacchi N; Friedman AD
    Leukemia; 1996 Jun; 10(6):984-90. PubMed ID: 8667656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular mechanism of blastic crisis in chronic myelocytic leukemia.
    Mitani K
    Leukemia; 1997 Apr; 11 Suppl 3():503-5. PubMed ID: 9209439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PRDX4, a member of the peroxiredoxin family, is fused to AML1 (RUNX1) in an acute myeloid leukemia patient with a t(X;21)(p22;q22).
    Zhang Y; Emmanuel N; Kamboj G; Chen J; Shurafa M; Van Dyke DL; Wiktor A; Rowley JD
    Genes Chromosomes Cancer; 2004 Aug; 40(4):365-70. PubMed ID: 15188461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia.
    Mitani K; Ogawa S; Tanaka T; Miyoshi H; Kurokawa M; Mano H; Yazaki Y; Ohki M; Hirai H
    EMBO J; 1994 Feb; 13(3):504-10. PubMed ID: 8313895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice.
    Cuenco GM; Ren R
    Oncogene; 2004 Jan; 23(2):569-79. PubMed ID: 14724585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual functions of the AML1/Evi-1 chimeric protein in the mechanism of leukemogenesis in t(3;21) leukemias.
    Tanaka T; Mitani K; Kurokawa M; Ogawa S; Tanaka K; Nishida J; Yazaki Y; Shibata Y; Hirai H
    Mol Cell Biol; 1995 May; 15(5):2383-92. PubMed ID: 7739522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leukemogenesis by the chromosomal translocations.
    Mitani K
    Leukemia; 1997 Apr; 11 Suppl 3():294-6. PubMed ID: 9209370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PEBP2 alpha B/mouse AML1 consists of multiple isoforms that possess differential transactivation potentials.
    Bae SC; Ogawa E; Maruyama M; Oka H; Satake M; Shigesada K; Jenkins NA; Gilbert DJ; Copeland NG; Ito Y
    Mol Cell Biol; 1994 May; 14(5):3242-52. PubMed ID: 8164679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The AML1/ETO(MTG8) and AML1/Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2beta(CBFbeta) in the nucleus more efficiently than wild-type AML1.
    Tanaka K; Tanaka T; Kurokawa M; Imai Y; Ogawa S; Mitani K; Yazaki Y; Hirai H
    Blood; 1998 Mar; 91(5):1688-99. PubMed ID: 9473235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells.
    Senyuk V; Chakraborty S; Mikhail FM; Zhao R; Chi Y; Nucifora G
    Oncogene; 2002 May; 21(20):3232-40. PubMed ID: 12082639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia.
    Cuenco GM; Ren R
    Oncogene; 2001 Dec; 20(57):8236-48. PubMed ID: 11781838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis.
    Shurtleff SA; Buijs A; Behm FG; Rubnitz JE; Raimondi SC; Hancock ML; Chan GC; Pui CH; Grosveld G; Downing JR
    Leukemia; 1995 Dec; 9(12):1985-9. PubMed ID: 8609706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The EVI1 gene in myeloid leukemia.
    Nucifora G
    Leukemia; 1997 Dec; 11(12):2022-31. PubMed ID: 9447815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel chromosomal translocation t(3;7)(q26;q21) in myeloid leukemia resulting in overexpression of EVI1.
    Storlazzi CT; Anelli L; Albano F; Zagaria A; Ventura M; Rocchi M; Panagopoulos I; Pannunzio A; Ottaviani E; Liso V; Specchia G
    Ann Hematol; 2004 Feb; 83(2):78-83. PubMed ID: 14551738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A unique AML1 (CBF2A) rearrangement, t(1;21)(p32;q22), observed in a patient with acute myelomonocytic leukemia.
    Cherry AM; Bangs CD; Jones P; Hall S; Natkunam Y
    Cancer Genet Cytogenet; 2001 Sep; 129(2):155-60. PubMed ID: 11566347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identical fusion transcript associated with different breakpoints in the AML1 gene in simple and variant t(8;21) acute myeloid leukemia.
    de Greef GE; Hagemeijer A; Morgan R; Wijsman J; Hoefsloot LH; Sandberg AA; Sacchi N
    Leukemia; 1995 Feb; 9(2):282-7. PubMed ID: 7869765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML.
    Cuenco GM; Nucifora G; Ren R
    Proc Natl Acad Sci U S A; 2000 Feb; 97(4):1760-5. PubMed ID: 10677531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MYND-less splice variants of AML1-MTG8 (RUNX1-CBFA2T1) are expressed in leukemia with t(8;21).
    Kozu T; Fukuyama T; Yamami T; Akagi K; Kaneko Y
    Genes Chromosomes Cancer; 2005 May; 43(1):45-53. PubMed ID: 15723339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1.
    Frank RC; Sun X; Berguido FJ; Jakubowiak A; Nimer SD
    Oncogene; 1999 Mar; 18(9):1701-10. PubMed ID: 10208431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significance of MTG8 in leukemogenesis.
    Kozu T; Komori A; Sueoka E; Fujiki H; Kaneko Y; Matsui T; Uehara T; Seino Y; Ishii M
    Leukemia; 1997 Apr; 11 Suppl 3():297-8. PubMed ID: 9209371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.